Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
A method is described to amplify the delivery of 111In to human breast cancer cells utilizing a novel human serum albumin-human EGF (HSA-hEGF) bioconjugate substituted preferentially in the HSA domain with multiple DTPA metal chelators for 111In. 111In-DTPA-HSA-hEGF exhibited a lower receptor-bindin...
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Journal article |
| Kieli: | English |
| Julkaistu: |
2001
|
| _version_ | 1826288719695446016 |
|---|---|
| author | Wang, J Chen, P Su, Z Vallis, K Sandhu, J Cameron, R Hendler, A Reilly, R |
| author_facet | Wang, J Chen, P Su, Z Vallis, K Sandhu, J Cameron, R Hendler, A Reilly, R |
| author_sort | Wang, J |
| collection | OXFORD |
| description | A method is described to amplify the delivery of 111In to human breast cancer cells utilizing a novel human serum albumin-human EGF (HSA-hEGF) bioconjugate substituted preferentially in the HSA domain with multiple DTPA metal chelators for 111In. 111In-DTPA-HSA-hEGF exhibited a lower receptor-binding affinity than 111In-DTPA-hEGF but was rapidly and specifically bound, internalized and translocated to the nucleus in EGFR-positive MDA-MB-468 breast cancer cells. 111In-DTPA-HSA-hEGF was cytotoxic in vitro mainly through the emission of short-range Auger electrons and partially through the effects of the hEGF moiety to MDA-MB-468 cells overexpressing EGFR (1-2 x 10(6) receptors/cell) but not towards MCF-7 breast cancer cells with a 100-fold lower level of EGFR on their surface. The cytotoxicity in vitro against MDA-MB-468 cells of 111In-DTPA-HSA-hEGF substituted with nine DTPA chelators was enhanced 4-fold compared to 111In-DTPA-hEGF monosubstituted with DTPA. Studies are planned to further evaluate 111In-DTPA-HSA-hEGF in vivo as a new imaging and targeted radiotherapeutic agent for breast cancer. |
| first_indexed | 2024-03-07T02:17:57Z |
| format | Journal article |
| id | oxford-uuid:a2eb0f1b-52fb-480d-ab83-0d5fcb231b64 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:17:57Z |
| publishDate | 2001 |
| record_format | dspace |
| spelling | oxford-uuid:a2eb0f1b-52fb-480d-ab83-0d5fcb231b642022-03-27T02:23:15ZAmplified delivery of indium-111 to EGFR-positive human breast cancer cells.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a2eb0f1b-52fb-480d-ab83-0d5fcb231b64EnglishSymplectic Elements at Oxford2001Wang, JChen, PSu, ZVallis, KSandhu, JCameron, RHendler, AReilly, RA method is described to amplify the delivery of 111In to human breast cancer cells utilizing a novel human serum albumin-human EGF (HSA-hEGF) bioconjugate substituted preferentially in the HSA domain with multiple DTPA metal chelators for 111In. 111In-DTPA-HSA-hEGF exhibited a lower receptor-binding affinity than 111In-DTPA-hEGF but was rapidly and specifically bound, internalized and translocated to the nucleus in EGFR-positive MDA-MB-468 breast cancer cells. 111In-DTPA-HSA-hEGF was cytotoxic in vitro mainly through the emission of short-range Auger electrons and partially through the effects of the hEGF moiety to MDA-MB-468 cells overexpressing EGFR (1-2 x 10(6) receptors/cell) but not towards MCF-7 breast cancer cells with a 100-fold lower level of EGFR on their surface. The cytotoxicity in vitro against MDA-MB-468 cells of 111In-DTPA-HSA-hEGF substituted with nine DTPA chelators was enhanced 4-fold compared to 111In-DTPA-hEGF monosubstituted with DTPA. Studies are planned to further evaluate 111In-DTPA-HSA-hEGF in vivo as a new imaging and targeted radiotherapeutic agent for breast cancer. |
| spellingShingle | Wang, J Chen, P Su, Z Vallis, K Sandhu, J Cameron, R Hendler, A Reilly, R Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. |
| title | Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. |
| title_full | Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. |
| title_fullStr | Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. |
| title_full_unstemmed | Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. |
| title_short | Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. |
| title_sort | amplified delivery of indium 111 to egfr positive human breast cancer cells |
| work_keys_str_mv | AT wangj amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells AT chenp amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells AT suz amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells AT vallisk amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells AT sandhuj amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells AT cameronr amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells AT hendlera amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells AT reillyr amplifieddeliveryofindium111toegfrpositivehumanbreastcancercells |